Literature DB >> 32794104

Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma.

Domenico Albano1, Mark Tulchinsky2, Francesco Dondi3, Angelica Mazzoletti3, Davide Lombardi4, Francesco Bertagna3, Raffaele Giubbini3.   

Abstract

PURPOSE: To investigate the potential role of serum thyroglobulin doubling time (TgDT) in predicting 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/CT results in patients affected by differentiated thyroid carcinoma (DTC) who demonstrated a combination of positive Tg but a negative [131I] whole-body scan ([131I]-WBS).
MATERIALS AND METHODS: Inclusion criteria were (1) prior [131I] treatment for DTC, (2) negative subsequent [131I]-WBS, (3) no interfering anti-Tg antibodies, (4) three consecutive Tg measurements under the thyroid hormone replacement therapy to calculate TgDT before 2-[18F]FDG PET/CT, and (5) at least 6 months of clinical and/or imaging follow-up to ascertain the diagnosis. Receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to identify the optimal cutoff point for the last stimulated Tg and TgDT prior to [18F]FDG PET/CT.
RESULTS: One hundred and thirteen patients were included. Seventy-four (65%) patients had positive [18F]FDG PET/CT for DTC recurrence, while the remaining 39 (35%) negative. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of [18F]FDG PET/CT were 92%, 94%, 97%, 87%, and 93%. Patients with positive [18F]FDG PET/CT had higher Tg and TgDT than those with negative PET/CT. ROC curve analysis revealed an optimal Tg cutoff of 19 ng/mL (sensitivity 78%, specificity 85%, AUC = 0.844) and TgDT of 2.5 years (sensitivity 93%, specificity 87%, AUC = 0.911). TgDT threshold of 2.5 years predicted significantly (p = 0.023) better than Tg level PET/CT results.
CONCLUSIONS: The diagnostic performance of [18F]FDG PET/CT could be significantly improved when TgDT is less than or equal to 2.5 years, as compared with using the absolute Tg level.

Entities:  

Keywords:  Diagnostic test performance; Differentiated thyroid carcinoma; Thyroglobulin; Thyroglobulin doubling time; [18F]FDG PET/CT

Year:  2020        PMID: 32794104      PMCID: PMC7835169          DOI: 10.1007/s00259-020-04992-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Authors:  Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt
Journal:  Thyroid       Date:  2003-01       Impact factor: 6.568

Review 2.  Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis.

Authors:  Rosângela Caetano; Cláudia Regina Garcia Bastos; Ione Ayala Gualandi de Oliveira; Rondineli Mendes da Silva; Clarisse Pereira Dias Drumond Fortes; Vera Lucia Edais Pepe; Lenice Gnocchi Reis; José Ueleres Braga
Journal:  Head Neck       Date:  2015-05-26       Impact factor: 3.147

Review 3.  Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma.

Authors:  Luca Giovanella
Journal:  Curr Opin Oncol       Date:  2020-01       Impact factor: 3.645

4.  Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.

Authors:  Xieyi Zhang; Tetsuya Higuchi; Hiroyasu Tomonaga; Oyunbold Lamid-Ochir; Anu Bhattarai; Huong Nguyen-Thu; Ayako Taketomi-Takahashi; Hiromi Hirasawa; Yoshito Tsushima
Journal:  Nucl Med Commun       Date:  2020-04       Impact factor: 1.690

Review 5.  Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review.

Authors:  Paolo Zanotti-Fregonara; Isabelle Keller; Marie Calzada-Nocaudie; Adil Al-Nahhas; Jean-Yves Devaux; Gaia Grassetto; Maria Cristina Marzola; Domenico Rubello; Elif Hindié
Journal:  Nucl Med Commun       Date:  2010-12       Impact factor: 1.690

6.  Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.

Authors:  Kiminori Sugino; Mitsuji Nagahama; Wataru Kitagawa; Keiko Ohkuwa; Takashi Uruno; Kenichi Matsuzu; Akifumi Suzuki; Chie Masaki; Junko Akaishi; Kiyomi Y Hames; Chisato Tomoda; Yuna Ogimi; Koichi Ito
Journal:  Endocr J       Date:  2017-12-21       Impact factor: 2.349

7.  Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.

Authors:  Meng-Jie Dong; Zhen-Feng Liu; Kui Zhao; Ling-Xiang Ruan; Guo-Lin Wang; Shu-Ye Yang; Fang Sun; Xu-Guang Luo
Journal:  Nucl Med Commun       Date:  2009-08       Impact factor: 1.690

8.  Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

Authors:  Johanna Wassermann; Marie-Odile Bernier; Jean-Philippe Spano; Charlotte Lepoutre-Lussey; Camille Buffet; Jean-Marc Simon; Fabrice Ménégaux; Frédérique Tissier; Monique Leban; Laurence Leenhardt
Journal:  Oncologist       Date:  2015-12-16

9.  Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines.

Authors:  Domenico Albano; Francesco Bertagna; Mattia Bonacina; Rexhep Durmo; Elisabetta Cerudelli; Maria Gazzilli; Maria Beatrice Panarotto; Anna Maria Formenti; Gherardo Mazziotti; Andrea Giustina; Raffaele Giubbini
Journal:  Eur J Endocrinol       Date:  2018-06-13       Impact factor: 6.664

10.  Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma.

Authors:  Akira Miyauchi; Takumi Kudo; Minoru Kihara; Takuya Higashiyama; Yasuhiro Ito; Kaoru Kobayashi; Akihiro Miya
Journal:  Endocr J       Date:  2012-11-23       Impact factor: 2.349

View more
  5 in total

1.  2-[18F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study.

Authors:  Stefano Gay; Stefano Raffa; Anna De'Luca di Pietralata; Matteo Bauckneht; Lara Vera; Alberto Miceli; Manuela Albertelli; Silvia Morbelli; Massimo Giusti; Diego Ferone
Journal:  Diagnostics (Basel)       Date:  2022-02-16

Review 2.  Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.

Authors:  Jing Li; Yingjie Zhang; Fenghao Sun; Ligang Xing; Xiaorong Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

3.  A Stepwise Approach Using Metastatic Lymph Node Ratio-Combined Thyroglobulin for Customization of [18F]FDG-PET/CT Indication to Detect Persistent Disease in Patients with Papillary Thyroid Cancer.

Authors:  Hong Hua Piao; Subin Jeon; Su Woong Yoo; Young Jae Ryu; Dong-Yeon Kim; Ayoung Pyo; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Diagnostics (Basel)       Date:  2021-05-06

4.  Prognostic Role of 2-[18F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET/CT.

Authors:  Domenico Albano; Francesco Dondi; Angelica Mazzoletti; Pietro Bellini; Carlo Rodella; Francesco Bertagna
Journal:  Diagnostics (Basel)       Date:  2021-11-25

5.  The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan.

Authors:  Domenico Albano; Mark Tulchinsky; Francesco Dondi; Angelica Mazzoletti; Francesco Bertagna; Raffaele Giubbini
Journal:  Endocrine       Date:  2021-05-20       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.